10-Q: Sanara MedTech Reports Q1 2026 Growth and Profitability

Sanara MedTech Inc. announced a 19% increase in net revenue for Q1 2026, driven by strong performance in soft tissue repair products, and achieved net income from continuing operations.

Summary

• Sanara MedTech Inc. reported net revenue of $27.8 million for the first quarter ended March 31, 2026, a 19% increase compared to $23.4 million in the same period of 2025.
• The company achieved net income from continuing operations of $0.4 million for Q1 2026, a significant improvement from a net loss of $0.6 million in Q1 2025.
• Adjusted EBITDA also saw substantial growth, reaching $4.3 million in Q1 2026, up from $2.7 million in Q1 2025.
• The company has discontinued its Tissue Health Plus (THP) segment, focusing exclusively on its surgical market products.
• Cash on hand at the end of Q1 2026 was $13.6 million, and the company believes it has sufficient liquidity for the next 12 months.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, a return to profitability from continuing operations, and improved EBITDA, despite ongoing debt obligations and operational cash burn.

Positives

• Net revenue increased by 19% to $27.8 million in Q1 2026 compared to $23.4 million in Q1 2025.
• Achieved net income from continuing operations of $0.4 million in Q1 2026, a turnaround from a net loss of $0.6 million in Q1 2025.
• Adjusted EBITDA increased by 59% to $4.3 million in Q1 2026 from $2.7 million in Q1 2025.
• Gross margin remained strong at approximately 93% in Q1 2026.
• BIASURGE product received an Innovative Technology contract from Vizient Inc., effective January 1, 2026.
• A peer-reviewed study published on March 11, 2026, demonstrated cost savings and improved health outcomes for CellerateRX Surgical in high-risk spinal surgery patients.

Negatives

• Accounts receivable increased by $1.7 million to $13.6 million in Q1 2026 compared to $12.0 million in Q4 2025.
• Inventory decreased by $0.8 million to $3.1 million in Q1 2026 compared to $3.9 million in Q4 2025.
• Accounts payable decreased significantly by $1.4 million to $0.9 million in Q1 2026 compared to $2.3 million in Q4 2025.
• Accrued bonuses and commissions decreased by $2.7 million to $9.1 million in Q1 2026 compared to $11.8 million in Q4 2025.
• Operating cash flow was negative at ($2.5 million) for Q1 2026, compared to ($2.0 million) for Q1 2025.
• The company incurred higher interest expense and fees related to the CRG Term Loan in Q1 2026.

Risks

• Shortfalls in forecasted revenue growth.
• Ability to meet future capital requirements.
• Ability to maintain compliance with debt obligations.
• Ability to develop and commercialize new products.
• Intense competition in the markets.
• Failure of products to obtain market acceptance.
• Effect of security breaches and other disruptions.
• Ability to maintain effective internal controls over financial reporting.
• Impact of competitors inventing superior products.
• Disruptions of distribution model, consumer base, or supply of products.
• Failure of third-party assessments to demonstrate desired outcomes.
• Protection of proprietary rights to technologies and impact of intellectual property infringement claims.
• Dependence on technologies and products licensed from third parties.
• Effects of current and future laws, rules, and regulations.
• Effect of defects, failures, or quality issues associated with products.

Future Outlook

The company believes its current cash on hand, combined with expected cash flows from operations, will be sufficient to fund its growth strategy and meet anticipated operating expenses and capital expenditures for at least the next 12 months. Future cash needs are expected for product portfolio development, clinical studies, debt repayment, and general corporate purposes.

Management Comments

• "Our companys main source of revenue has consistently been from soft tissue repair and bone fusion products for the surgical market."
• "To further support our surgical business, particularly in wound care, we launched a value-based wound care services initiative designed to enhance outcomes while complementing our offerings in both surgical and post-acute markets."
• "Persistent losses related to THP and a lack of any firm commitments from potential investors led management and our Board of Directors to decide to discontinue THPs operations in mid-September 2025 and shift our focus exclusively on products and technologies for use in the surgical market."
• "For the three months ended March 31, 2026, our Adjusted EBITDA was $4.3 million compared to $2.7 million for the three months ended March 31, 2025. Higher Adjusted EBITDA in the first quarter of 2026 was primarily due to net revenue growth offset by increases in SG&A."

Industry Context

StockSavvy.ai notes that Sanara MedTech's Q1 2026 results reflect a strategic pivot towards its core surgical market, evidenced by the discontinuation of the THP segment. The reported revenue growth and improved profitability align with a broader trend in the medical technology sector focusing on specialized, high-margin surgical solutions.

Comparison to Industry Standards

• The company's gross margin of approximately 93% is exceptionally high, suggesting strong pricing power and efficient cost management for its specialized surgical products. This is generally above the average gross margins seen in broader medical device sectors, which can range from 50-70%.
• The 19% year-over-year revenue growth in Q1 2026 is robust, particularly for a company in the medical technology space, indicating successful market penetration and expansion of its distribution network.
• The significant increase in Adjusted EBITDA (59% YoY) demonstrates improved operational efficiency and profitability, a key metric closely watched by investors in the healthcare industry.
• The company's focus on soft tissue repair and bone fusion products places it in competitive but growing segments of the surgical market. Competitors in these areas include larger, established players as well as specialized firms, making consistent innovation and market access crucial.

Legal Proceedings

• To the company's knowledge, there are no material pending legal proceedings to which it is a party or of which any of its property is the subject.

Related Party Transactions

• License agreement with Rochal Industries, LLC for antimicrobial products, with royalties of 2-4% of net sales and minimum annual royalties.
• License agreement with Rochal for antimicrobial barrier film and skin protectant products, with royalties of 2-4% of net sales and increasing minimum annual royalties.
• License agreement with Rochal for a debrider product (impairment charge of $1.2 million recorded in Q4 2025).
• Consulting agreement with Ann Beal Salamone, a director, for $177,697 annually.
• Transaction Advisory Services Agreement with The Catalyst Group Inc. (Catalyst), with costs incurred of $850 in Q1 2026 and $20,000 in Q1 2025.
• Related party payables totaling $15,847 at March 31, 2026.

Stakeholder Impact

• Shareholders: Improved financial performance with net income and increased Adjusted EBITDA may positively impact shareholder value. The company's focus on core surgical products could lead to more predictable revenue streams.
• Employees: The discontinuation of the THP segment may have led to workforce reductions in that area. Continued focus on surgical products may create opportunities in sales and R&D.
• Creditors: The company is managing its debt obligations, including the CRG Term Loan, and is currently in compliance with covenants. Continued revenue growth and profitability are crucial for debt servicing.
• Customers (Hospitals/Surgical Centers): Continued availability and potential innovation in soft tissue repair and bone fusion products are beneficial. The Vizient contract for BIASURGE may offer cost advantages.
• Suppliers: The company's ability to manage its supply chain and cost of goods sold will impact its profitability, which in turn affects its ability to meet obligations to suppliers.

Next Steps

• Continue to expand and develop the independent distribution network in new and existing U.S. markets.
• Advance the pipeline of next-generation products.
• Focus on developing and commercializing surgical product portfolio.
• Continue to incur minimal costs related to winding down THP through Q2 and Q3 2026.
• The Petito Services Agreement will terminate effective August 1, 2026.
• The exclusive license agreement with Tufts University terminated effective April 20, 2026, and the company is in the process of dissolving SCP.

Key Dates

Recommendation

The company shows positive momentum with revenue growth and a return to profitability. However, the significant debt load, negative operating cash flow, and the strategic shift away from a previously incubated segment warrant a cautious approach. Investors should monitor debt covenants, cash flow generation, and the success of the focused surgical product strategy before considering a stronger buy recommendation.

Keywords

Sanara MedTech, 10-Q, Quarterly Report, Medical Technology, Surgical Products, Soft Tissue Repair, Bone Fusion, Financial Results, Revenue Growth, Adjusted EBITDA, Continuing Operations, Discontinued Operations, CRG Term Loan